Bulletin from the extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB on 23 April 2024

Today, on 23 April 2024, an extraordinary general meeting, and the first meeting for liquidation purposes, was held in Qlife Holding AB. A summary of the adopted resolutions follows below.

Resolution on whether the company shall enter into liquidation or continue its operations
The extraordinary general meeting resolved in accordance with the primary proposal from the board of directors that the company’s operations shall be continued. The resolution on continued operations means that the general meeting shall be convened within eight months of this first meeting for liquidation purposes in order to re-examine the question on whether the company should enter into liquidation (second meeting for liquidation purposes).

Resolution on (A) amendment of the Articles of Association; and (B) reduction of the share capital to cover loss
The extraordinary general meeting resolved in accordance with the proposal from the board of directors to amend the provisions in the Articles of Association regarding the limits for the company’s share capital. In addition, the extraordinary general meeting resolved to reduce the company’s share capital by SEK 38,252,899.474350 to cover loss and without redemption of shares. Through the reduction, the share capital decreases from SEK 51,980,016.5106 to SEK 13,727,117.03625, whereby the share’s quota value decreases from SEK 0.0142 to SEK 0.00375 per share.

Resolution on authorization regarding issues of shares, warrants and/or convertibles
The extraordinary general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors, within the limits of the company’s Articles of Association, at one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders’ preferential rights, to resolve to issue new shares, warrants and/or convertibles. Issues may be made with or without provisions regarding payment in kind or through set-off or other provisions. The purpose of the authorization is to enable the company to raise working capital and to provide the company with financial freedom of action. To the extent an issue is made with deviation from the shareholders’ preferential rights, the issue should be made on market terms (subject to customary new issue discount, as applicable).

This information was submitted for publication, through the agency of the contact person set out above, on 23-04-2024 09:55 CET

For more information, please contact: 

Thomas Warthoe
Chief Executive Officer (CEO)
Phone: +45 21 63 35 34
E-mail: tw@egoo.health

Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (”Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.